Applying Nanotechnology to Life Sciences With Zyvex Spinout NanoMed

Zyvex Labs today announced its first company spinout: NanoMed, Inc. The new company was started by Rob Burgess, PhD, former Vice President of Research & Development at Zyvex Instruments, and Gareth Hughes, PhD, former Group Leader of Life Sciences at Zyvex Corporation.

NanoMed is focused on the application of nanotechnology in Life Sciences. The company seeks to apply nanoparticle technologies for the development of research grade reagents and cutting-edge therapeutics. In addition, NanoMed possesses a strong collection of nanotechnology platforms that are currently available for licensing. The new company leverages Zyvex's existing Life Science patents, proprietary methods, and core technologies.

"We are delighted to obtain assignment of the nanoparticle dispersion intellectual property from Zyvex Labs," said Rob Burgess, Ph.D., NanoMed's Co-Founder and Chairman of the Board. "The application of Zyvex Performance Materials' Kentera and other polymers for functionalizing carbon nanotubes will play an integral role in solidifying NanoMed's portfolio of cutting-edge nanotechnologies as they relate to the biomedical sciences. We look forward to continuing a productive partnership with Zyvex Labs and Zyvex Performance Materials."

"Rob is a focused leader with outstanding technology development skills," said Zyvex Founder Jim Von Ehr. "He also has a proven track record in growing businesses. I expect to see exciting new products from this new venture."

NanoMed's focus centers around the functionalization and specific delivery of nanoparticles for applications in various biomedical markets, including the research, diagnostics, therapeutics, and veterinary sectors. In collaboration with their strategic partners, NanoMed researchers have developed promising technologies that will allow for the effective use of nanotechnology-based solutions to address a variety of issues across multiple scientific disciplines, including basic biomedical research and applied science related to disorders such as cancer and infectious diseases.

Other founders include Rocky Draper, PhD, Professor at the University of Texas at Dallas, and Ellen Vitetta, PhD, Professor and Director of the Cancer Immunobiology Center at the University of Texas Southwestern Medical Center in Dallas.

Posted  22nd August 2007

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Zyvex. (2019, March 19). Applying Nanotechnology to Life Sciences With Zyvex Spinout NanoMed. AZoNano. Retrieved on October 03, 2024 from https://www.azonano.com/news.aspx?newsID=4778.

  • MLA

    Zyvex. "Applying Nanotechnology to Life Sciences With Zyvex Spinout NanoMed". AZoNano. 03 October 2024. <https://www.azonano.com/news.aspx?newsID=4778>.

  • Chicago

    Zyvex. "Applying Nanotechnology to Life Sciences With Zyvex Spinout NanoMed". AZoNano. https://www.azonano.com/news.aspx?newsID=4778. (accessed October 03, 2024).

  • Harvard

    Zyvex. 2019. Applying Nanotechnology to Life Sciences With Zyvex Spinout NanoMed. AZoNano, viewed 03 October 2024, https://www.azonano.com/news.aspx?newsID=4778.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.